SI-BONE Reports Strong Preliminary Q4 & Full Year 2025 Revenue Growth and Achieves Third Consecutive Quarter of Cashflow Breakeven

summarizeSummary

SI-BONE reported strong preliminary Q4 and full year 2025 revenue growth, alongside achieving net cashflow breakeven for the third consecutive quarter and significant growth in active U.S. physicians.

check_boxKey Events

• Preliminary Q4 2025 Revenue

  Reported worldwide revenue between $56.2 - $56.3 million, representing approximately 15% growth year-over-year.

• Preliminary FY 2025 Revenue

  Announced worldwide revenue between $200.8 - $200.9 million for the full fiscal year 2025, reflecting approximately 20% growth.

• Net Cashflow Breakeven Achieved

  Achieved net cashflow breakeven for the third consecutive quarter, with cash and equivalents of approximately $147.7 million.

• Growth in Active U.S. Physicians

  Increased active U.S. physicians to approximately 1,640, an 18% growth year-over-year, indicating strong market adoption.

auto_awesomeAnalysis

SI-BONE, Inc. announced robust preliminary financial results for the fourth quarter and full year 2025, demonstrating significant operational momentum. The company achieved worldwide revenue growth of approximately 15% in Q4 and 20% for the full year, indicating strong demand for its products. A key highlight is the achievement of net cashflow breakeven for the third consecutive quarter, which is a positive signal for financial stability and sustainability. The substantial increase in active U.S. physicians also points to successful market penetration and adoption of its procedural solutions. While these results are preliminary and unaudited, they provide a strong positive outlook ahead of the full earnings report.